AKESO(09926),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

09926 AKESO

Noon Closed 02-02 12:05:00

98.200

-12.200

-11.05%

High109.000	Low98.050	Vol14.47M
Open109.000	D1 Closing110.400	Amplitude9.92%
Mkt Cap90.44B	Tradable Cap90.44B	Total Shares921.00M
T/O1.46B	T/O Rate1.57%	Tradable Shares921.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"09926","market":"HK","secType":"STK","nameCN":"AKESO","latestPrice":98.2,"timestamp":1770005100009,"preClose":110.4,"halted":0,"volume":14470955,"delay":0,"changeRate":-0.11050724637681161,"floatShares":921000000,"shares":921000000,"eps":-0.604581,"marketStatus":"Noon Closed","change":-12.2,"latestTime":"02-02 12:05:00","open":109,"high":109,"low":98.05,"amount":1461296374,"amplitude":0.099185,"askPrice":98.25,"askSize":14000,"bidPrice":98.2,"bidSize":3000,"shortable":3,"etf":0,"ttmEps":-1.007,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1770008400000},"marketStatusCode":3,"adr":0,"listingDate":1587657600000,"exchange":"SEHK","adjPreClose":110.4,"openAndCloseTimeList":[[1769995800000,1770004800000],[1770008400000,1770019200000]],"volumeRatio":5.630296,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"AKS.HK","impliedVol":0.2868,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/09926","defaultTab":"news","newsList":[{"id":"2606216424","title":"Akeso Updates Contract Manufacturing Arrangement with Supplemental Agreement Expiry Set for 2039","url":"https://stock-news.laohu8.com/highlight/detail?id=2606216424","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606216424?lang=en_us&edition=fundamental","pubTime":"2026-01-26 18:11","pubTimestamp":1769422310,"startTime":"0","endTime":"0","summary":"Akeso Inc. announced further information regarding its ongoing contract manufacturing arrangement involving CTTQ-Akeso, Akeso Biopharma, Chai Tai Tianqing, and Nanjing Tianqing. The company clarified that the term of the Supplemental Agreement is fixed until August 29, 2039, with the possibility for parties to enter into a new agreement upon expiry, subject to necessity, product sales performance, and prevailing circumstances. The annual procurement caps for monoclonal antibody  products under the agreement were determined by considering historical procurement amounts, anticipated market demand growth, and potential price or demand fluctuations. The procurement price will be based on actual manufacturing costs plus a reasonable profit margin, taking into account raw material costs, manufacturing scale, and profit margins of comparable publicly listed contract manufacturers, with adjustments for specific manufacturing processes.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nNDL4nL5zQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU0348825331.USD","LU0417516738.SGD","LU0561508036.HKD","LU0348827113.USD","LU2399975544.HKD","LU2476274720.SGD","LU0540923850.HKD","LU0348735423.USD","LU0634319403.HKD","IE00B5MMRT66.SGD","LU0417516902.SGD","IE00BPRC5H50.USD","LU0348767384.USD","LU0348783233.USD","LU1794554557.SGD","IE00B543WZ88.USD","LU1720050803.USD","LU2488822045.USD","LU0348784397.USD","LU1961090484.USD","LU2778985437.USD","LU0348766576.USD","09926","LU0417516571.SGD","LU2476274308.USD","BK1574"],"gpt_icon":0},{"id":"2605923955","title":"Gumokimab sNDA Acceptance for Ankylosing Spondylitis Could Be A Game Changer For Akeso (SEHK:9926)","url":"https://stock-news.laohu8.com/highlight/detail?id=2605923955","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605923955?lang=en_us&edition=fundamental","pubTime":"2026-01-24 17:32","pubTimestamp":1769247139,"startTime":"0","endTime":"0","summary":"Earlier this month, Akeso announced that China’s National Medical Products Administration accepted its supplemental New Drug Application for gumokimab (AK111), an anti‑IL‑17A antibody for active ankylosing spondylitis, supported by positive Phase III data. \nThis milestone highlights Akeso’s expanding non‑oncology portfolio and the potential for gumokimab to address a large ankylosing spondylitis patient population in China. \nWe’ll now examine how gumokimab’s sNDA acceptance, supported by...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/gumokimab-snda-acceptance-for-ankylosing-spondylitis-could-b","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/gumokimab-snda-acceptance-for-ankylosing-spondylitis-could-b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2476274308.USD","LU1794554557.SGD","LU0348767384.USD","LU0348766576.USD","LU2778985437.USD","LU2399975544.HKD","IE00B543WZ88.USD","BK1161","LU0348825331.USD","LU2488822045.USD","LU1720050803.USD","09926","BK1574","LU2476274720.SGD","LU0348827113.USD","LU0417516738.SGD","LU0561508036.HKD","LU0348735423.USD","LU0348784397.USD","IE00BPRC5H50.USD","LU0634319403.HKD","LU0348783233.USD","IE00B5MMRT66.SGD","LU0417516571.SGD","LU0540923850.HKD","LU1961090484.USD","LU0417516902.SGD"],"gpt_icon":0},{"id":"1142659698","title":"Hong Kong Stock Innovative Drug Concept Continues Rally, Akeso Surges Over 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1142659698","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142659698?lang=en_us&edition=fundamental","pubTime":"2026-01-23 10:31","pubTimestamp":1769135501,"startTime":"0","endTime":"0","summary":"On January 23, the innovative drug concept in Hong Kong stocks continued its upward trajectory. Everest Medicines surged over 7%, while XtalPi Holdings and Akeso rose more than 4%. Kelun-Biotech...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0634319403.HKD","LU1720050803.USD","LU0348825331.USD","LU1794554557.SGD","LU1961090484.USD","LU0417516571.SGD","LU0540923850.HKD","LU2476274308.USD","BK1610","06978","LU0348827113.USD","LU0417516738.SGD","IE00BPRC5H50.USD","09926","LU2399975544.HKD","IE00B543WZ88.USD","LU2476274720.SGD","LU0417516902.SGD","02800","LU0348766576.USD","LU2778985437.USD","LU0348784397.USD","BK1574","LU0348783233.USD","LU2488822045.USD","159992","IE00B5MMRT66.SGD","LU0348767384.USD","LU0348735423.USD","LU0561508036.HKD","BK1161"],"gpt_icon":1},{"id":"1116688046","title":"AKESO Surges Over 5% in Early Trading as Second Indication for Self-Developed Gumokimab Receives NDA Acceptance","url":"https://stock-news.laohu8.com/highlight/detail?id=1116688046","media":"Deep News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116688046?lang=en_us&edition=fundamental","pubTime":"2026-01-23 10:26","pubTimestamp":1769135178,"startTime":"0","endTime":"0","summary":"AKESO (09926) rose more than 5% in early trading. At the time of writing, the stock was up 5.25% to HK$118.30, with a turnover of HK$377 million. According to an announcement on AKESO's official...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU0561508036.HKD","LU0417516902.SGD","LU0348783233.USD","LU0634319403.HKD","LU0417516571.SGD","IE00BPRC5H50.USD","LU2778985437.USD","LU0417516738.SGD","LU1720050803.USD","LU0348766576.USD","LU1961090484.USD","IE00B5MMRT66.SGD","LU0540923850.HKD","IE00B543WZ88.USD","LU2476274720.SGD","LU2488822045.USD","BK1574","LU0348827113.USD","LU0348735423.USD","LU0348767384.USD","LU1794554557.SGD","LU0348825331.USD","LU0348784397.USD","LU2399975544.HKD","LU2476274308.USD","09926"],"gpt_icon":0},{"id":"2605668469","title":"Akeso (SEHK:9926) Valuation Check After Recent Share Price Pullback","url":"https://stock-news.laohu8.com/highlight/detail?id=2605668469","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605668469?lang=en_us&edition=fundamental","pubTime":"2026-01-22 14:36","pubTimestamp":1769063769,"startTime":"0","endTime":"0","summary":"Why Akeso is on investors’ radars today\nAkeso (SEHK:9926) has attracted fresh attention after recent share price moves, with the stock showing a 1 day return of 3.1% decline and a 7 day return of 7.6% decline from its last close of HK$114. Investors are weighing these short term moves against its longer term record and the company’s current fundamentals.\nSee our latest analysis for Akeso.\nWhile the recent 1 day and 7 day share price returns are both in decline, Akeso’s 1 year total...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/akeso-sehk9926-valuation-check-after-recent-share-price-pull","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/akeso-sehk9926-valuation-check-after-recent-share-price-pull","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0348767384.USD","LU0634319403.HKD","IE00B543WZ88.USD","LU2476274308.USD","IE00B5MMRT66.SGD","BK1161","LU0348735423.USD","LU0348783233.USD","LU0348766576.USD","LU2488822045.USD","LU0561508036.HKD","LU1961090484.USD","LU2476274720.SGD","LU2399975544.HKD","LU0417516571.SGD","DCF","LU0348825331.USD","LU0417516902.SGD","LU0348784397.USD","09926","LU0348827113.USD","LU0417516738.SGD","LU0540923850.HKD","LU2778985437.USD","LU1720050803.USD","IE00BPRC5H50.USD","BK1574","LU1794554557.SGD"],"gpt_icon":0},{"id":"2604138587","title":"Akeso sNDA for Gumokimab in Ankylosing Spondylitis Accepted for NMPA Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2604138587","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604138587?lang=en_us&edition=fundamental","pubTime":"2026-01-19 19:25","pubTimestamp":1768821905,"startTime":"0","endTime":"0","summary":"Akeso Inc. announced that the National Medical Products Administration  in China has accepted the supplemental New Drug Application  for gumokimab , a humanized anti-IL-17A monoclonal antibody, for the treatment of active ankylosing spondylitis. This marks the second indication for gumokimab to receive NDA review, following its earlier acceptance for moderate-to-severe psoriasis. The NDA acceptance is supported by positive results from a pivotal Phase III clinical trial, which demonstrated significant improvements in symptoms and quality of life for patients with active ankylosing spondylitis.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via PR Newswire  on Ja","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260119:nNDL9r8TQl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1720050803.USD","LU2476274308.USD","IE00B5MMRT66.SGD","LU0348784397.USD","LU0561508036.HKD","BK1574","IE00BPRC5H50.USD","LU0348825331.USD","LU1794554557.SGD","LU0348783233.USD","09926","LU0417516571.SGD","LU0634319403.HKD","LU2778985437.USD","LU1961090484.USD","BK1161","IE00B543WZ88.USD","LU0417516902.SGD","LU0417516738.SGD","LU2488822045.USD","LU2476274720.SGD","LU0348735423.USD","LU0540923850.HKD","LU0348827113.USD","LU2399975544.HKD","LU0348766576.USD","LU0348767384.USD"],"gpt_icon":0},{"id":"2604366138","title":"Akeso Announces Nmpa Acceptance of Second Nda for Gumokimab (Il-17a Inhibitor) in Active Ankylosing Spondylitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2604366138","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604366138?lang=en_us&edition=fundamental","pubTime":"2026-01-19 19:24","pubTimestamp":1768821890,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260119:nTUA2XB9Z3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","LU0348825331.USD","LU0417516738.SGD","LU0561508036.HKD","LU0348827113.USD","LU2399975544.HKD","LU2476274720.SGD","LU0540923850.HKD","LU0348735423.USD","LU0634319403.HKD","IE00B5MMRT66.SGD","LU0417516902.SGD","IE00BPRC5H50.USD","LU0348767384.USD","LU0348783233.USD","LU1794554557.SGD","IE00B543WZ88.USD","LU1720050803.USD","LU2488822045.USD","LU0348784397.USD","LU1961090484.USD","LU2778985437.USD","LU0348766576.USD","09926","LU0417516571.SGD","LU2476274308.USD","BK1574"],"gpt_icon":0},{"id":"1168374108","title":"CICC Hong Kong Stock Connect and Hang Seng Index Adjustment Preview: Zijin Gold Intl (02259) Among Potential Hang Seng Index Additions; 44 Companies Expected to Enter Stock Connect","url":"https://stock-news.laohu8.com/highlight/detail?id=1168374108","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168374108?lang=en_us&edition=fundamental","pubTime":"2026-01-19 14:24","pubTimestamp":1768803841,"startTime":"0","endTime":"0","summary":"According to a research report from CICC, Hang Seng Indexes Company will announce the official results of the Hang Seng Index Series review after the market close on Friday, February 13, 2026, with...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02601","MCHmain","HK0000252152.HKD","HK0000500386.USD","SGXZ86797644.SGD","ONC","LU2543165471.USD","BK1198","XPEV","09868","513600","SGXZ62798434.SGD","09987","02259","YUMC","688235","HK0000252160.HKD","02328","LU0593848301.USD","HHImain","06160","09926","06181","LU2213484517.USD","601601","02833","BK4614"],"gpt_icon":1},{"id":"2603366565","title":"Akeso Reports Cadonilimab Outperforms PD-1 Inhibitors in First-Line PD-L1-Low Gastric Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2603366565","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603366565?lang=en_us&edition=fundamental","pubTime":"2026-01-14 11:54","pubTimestamp":1768362882,"startTime":"0","endTime":"0","summary":"Akeso Inc. has announced results from a real-world study comparing cadonilimab plus chemotherapy to a PD-1 inhibitor plus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction cancer with PD-L1 CPS <5. The findings, presented at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium , indicate that the cadonilimab regimen significantly improved both overall survival  and progression-free survival  compared to the PD-1 inhibitor group. The objective response rate was also higher in the cadonilimab group . Safety profiles were comparable between the two groups, with no significant difference in grade 3-4 adverse events. The full study has been accepted for publication in the Journal of Gastrointestinal Oncology. Akeso is also advancing prospective Phase III studies, including the COMPASSION-37 trial, which received FDA approval to initiate at the end of 2025.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nNDL6SDyTW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU0417516738.SGD","LU0561508036.HKD","LU0348827113.USD","LU2476274308.USD","LU0348825331.USD","IE00B543WZ88.USD","LU0417516902.SGD","LU2778985437.USD","LU1794554557.SGD","LU2488822045.USD","LU1961090484.USD","09926","LU0348766576.USD","LU0417516571.SGD","IE00B5MMRT66.SGD","LU2476274720.SGD","BK1574","LU0348784397.USD","LU0348735423.USD","LU0348767384.USD","LU1720050803.USD","IE00BPRC5H50.USD","LU2399975544.HKD","LU0348783233.USD","LU0634319403.HKD","LU0540923850.HKD"],"gpt_icon":0},{"id":"1132249843","title":"Zhutong Hong Kong Stock Connect Active Trading | January 13","url":"https://stock-news.laohu8.com/highlight/detail?id=1132249843","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132249843?lang=en_us&edition=fundamental","pubTime":"2026-01-13 19:14","pubTimestamp":1768302845,"startTime":"0","endTime":"0","summary":"On January 13, 2026, Alibaba-W (09988), Tencent Holdings (00700), and Xiaomi Group-W (01810) ranked as the top three stocks by turnover value on the Shanghai-Hong Kong Stock Connect (Southbound),...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999015978.USD","BK1501","LU1960683339.HKD","LU0477156797.USD","LU1328615791.USD","LU1642822792.SGD","LU0048597586.USD","IE00BPRC5H50.USD","LU1785774172.SGD","LU0650527681.SGD","LU1634259557.SGD","LU0314109678.HKD","LU2399975544.HKD","LU0029875118.USD","BK1608","LU2097828805.USD","LU1725190679.HKD","LU0882747503.HKD","LU0856984785.SGD","LU1064130708.USD","SG9999001846.SGD","BK4579","SGXZ90724238.SGD","LU1548497426.USD","LU0708995583.HKD","LU0329678337.USD","01024","GB00BDT5M118.USD","LU0210527791.USD","IE0001KFT4U8.USD","BK1517","LU0348816934.USD","LU1051768304.USD","LU1196710351.USD","LU1868837722.USD","LU1831875114.USD","LU0310800965.SGD","LU0661504455.SGD","LU0143863198.USD","LU2226246903.HKD","HK0000320223.HKD","BK1152","BK1531","IE00BZ08YR35.GBP","LU0345775950.USD","LU0819123356.HKD","SG9999017495.SGD","LU0128522157.USD","LU1251922891.USD","LU1634259391.SGD","IE0008368411.USD","LU1733274390.USD","SG9999006514.SGD","LU0244354667.USD","LU2023250504.SGD","LU0791590937.USD","HK0000252160.HKD","SG9999004220.SGD","LU0683595622.HKD","BK4524","09926","LU0203345920.USD","LU0509642566.USD","BK1528","LU1522347837.USD","BK4585","LU0287142896.SGD","BK1238","LU0762542818.HKD","LU0593848301.USD","LU0047713382.USD","BK4575","BK4614","LU0261950983.USD","LU0633140727.USD","LU1196710195.USD","LU0499858602.USD","LU0501845795.SGD","METmain","SG9999014880.SGD","LU0348825331.USD","LU0608807433.USD","BK4504","IE00B5MMRT66.SGD","LU0594300419.USD","SG9999001093.SGD","BK1523","002202","IE00B0169N27.USD","BK4505","LU1188198961.HKD","HMTD.SI","BK1576","LU1515016050.SGD","LU0675040207.SGD","LU0828238088.HKD","LU0577902454.USD","BK4543","LU0762541174.USD","LU1044876610.USD","SG9999000459.SGD","LU0049853897.USD","LU0985320562.USD","LU0072462343.USD","LU2237443622.USD","SG9999000418.SGD","81810","LU1196710864.SGD","LU0648948544.HKD","LU2152927971.USD","LU1226288253.USD","HXXD.SI","IE00BQXX3D17.EUR","IE00B543WZ88.USD","LU0651947912.USD","LU1769817096.USD","LU0348783662.USD","LU0251143458.SGD","LU2498475776.HKD","LU1282651121.HKD","LU0871576103.HKD","BK1513","LU1366334578.USD","LU3063872942.SGD","LU0880133367.SGD","LU1807302812.USD","LU0823040885.USD","LU0531970944.HKD","IE00B8L5B284.USD","LU0328353924.USD","IE0034224299.USD","LU1282649141.HKD","BK1586","LU0165289439.USD","LU0164872284.USD","LU1102505762.USD","LU1794554557.SGD","BK1610","LU1951186391.HKD","WXXWY","SG9999002463.SGD","LU0149534421.HKD","LU0231483743.USD","HK0000914686.HKD","LU0588545904.SGD","HK0000252152.HKD","81024","LU1046421795.USD","LU1152091168.USD","LU0823041008.USD","LU2778985437.USD","HK0000165453.HKD","LU0862451753.SGD","LU0823039010.USD","IE00B031J352.USD","LU0708995153.HKD","LU1226287792.SGD","LU0502904849.HKD","LU0320764243.SGD","LU0572944931.SGD","IE00B0169L03.USD","LU1720050803.USD","LU1048484197.HKD","LU1655091459.SGD","LU1675838814.USD","BK1163","LU1813983027.USD","LU1282649810.SGD","LU1568876251.USD","LU0831093199.SGD","LU1981816686.USD","HTCD.SI","LU0791591158.USD","LU1804176565.USD","LU0456827905.SGD","LU0823426480.USD","KSTmain","LU1366334651.USD","LU0572939691.SGD","LU0797268264.HKD","LU0577902538.SGD","LU1023057109.AUD","LU0348767384.USD","BK1618","LU0039217434.USD","LU0588546209.SGD","LU1568876335.HKD","HK0000320264.USD","LU0823413587.USD","LU0819121731.USD","LU1105468828.SGD","LU1439102457.SGD","LU2237443978.SGD","LU1720051108.HKD","LU0972618739.USD","BK4535","LU1880383366.USD","LU1883866441.USD","LU0127658192.USD","LU0228659784.USD","LU0441854154.USD","LU1282648689.USD","HK0000914660.USD","IE00BQXX3C00.GBP","IE0008368742.USD","SG9999015945.SGD","LU1719994722.HKD","LU0531971595.HKD","SG9999001069.SGD","00941","LU0737861772.HKD","LU0449509016.USD","LU0320764599.SGD","LU0348814723.USD","BK1590","LU1770034418.SGD","LU2051468812.USD","LU0516422366.SGD","HK0000500386.USD","HK0000352382.USD","SG9999015986.USD","LU0307460666.USD","LU0072913022.USD","LU0048580855.USD","LU0651946864.USD","LU0235996351.USD","LU2125910849.SGD","LU2293587155.HKD","BK4565","LU0251144936.SGD","LU0918141705.HKD","LU0417516738.SGD","LU0359202008.SGD","IE0008369823.USD","LU0516422440.USD","BK4531","BK4607","SGXZ31699556.SGD","LU0545039389.USD","LU0918141887.USD","BK1506","IE00B3M56506.USD","LU0348827113.USD","LU0823038988.USD","LU1497734951.SGD","HK0000306701.USD","LU1226287875.USD","BK4527","LU0414403682.SGD","LU0541501648.USD","LU0348766576.USD","BK1546","SG9999015952.SGD","LU0396098781.USD","LU2087589342.USD","SGXZ49509284.SGD","LU0259732245.USD","LU0886674414.USD","LU0130518102.USD","LU0700851271.USD","LU0269904917.USD","LU2097828474.EUR","BK1594","SG9999002828.SGD","LU0561508036.HKD","LU0084288322.USD","LU0640798160.USD","BK1591","00700","LU0052756011.USD","LU2148611432.USD","LU2008162690.USD","LU2237443382.USD","BK4534","LU0516423091.SGD","LU0164865239.USD","SG9999000327.SGD","SGXZ99366536.SGD","LU1242518857.USD","LU0128522744.USD","LU2242644610.SGD","SG9999001689.USD","LU0642271901.SGD","SG9999014674.SGD","LU1814569148.SGD","LU2362541273.HKD","LU0979878070.USD","BK4538","LU1048588211.SGD","IE0003895053.USD","LU0784639295.USD","LU1880398554.USD","LU2133065610.SGD","LU0181495838.USD","LU0106959298.USD","LU0543330566.HKD","LU1328277881.USD","LU1974910355.USD","LU0499858438.USD","LU2257852520.SGD","LU1733274473.HKD","BK4548","LU2237443549.SGD","SG9999018857.SGD","BK4122","LU0192582467.USD","LU0630378429.USD","LU1235295612.USD","BK1589","LU0821914370.USD","02208","LU2279701549.SGD","LU1282651048.USD","LU1504937902.USD","LU0831103253.SGD","LU1226287529.USD","LU0541502299.USD","LU0175139822.USD","IE00BZ08YT58.USD","BK1607","LU0011963245.USD","LU0029874905.USD","BK4502","IE00B067MR52.USD","IE00BMPRXN33.USD","SG9999013353.USD","LU2251237306.USD","LU1769817179.HKD","LU1044875133.USD","LU0143863784.USD","LU1211504680.USD","BK1615","BK1609","LU0149721374.USD","LU0890818403.SGD","LU0738911758.USD","SG9999001051.SGD","LU2247934214.USD","LU0051755006.USD","LU0164880469.USD","LU0196878994.USD","LU0326948709.USD","LU0630378692.HKD","LU0049112450.USD","SG9999007991.SGD","LU0762540952.USD","BK1617","LU0054237671.USD","LU2449936058.SGD","LU2462611646.USD","IE00BGV7N243.SGD","LU1242518931.SGD","LU0828237510.HKD","LU0672654166.SGD","LU0577902298.EUR","LU0648000940.SGD","SG9999001903.USD","BK4558","IE0009570106.USD","BK1588","LU1880398471.USD","IE0031814852.USD","LU0865486749.SGD","LU1497733631.SGD","LU2237443465.HKD","BK1583","IE00B0JY6N72.USD","LU0264606111.USD","600941","LU0061477393.USD","LU0320764755.SGD","00981","LU0043850808.USD","BABA","LU0348735423.USD","LU0823413660.USD","LU1051769294.HKD","LU0543330483.HKD","LU0052750758.USD","BK1574","LU0261947096.USD","SGXZ81514606.USD","LU1629966141.USD","LU2328871848.SGD","BK1142","LU0634319403.HKD","LU0898667661.SGD","LU0326950275.SGD","LU1282649067.USD","LU1226288097.SGD","LU1316542783.SGD","LU0289960550.SGD","LU0130103400.USD","XIACY","IE00B97KM107.HKD","BK1521","03690","LU0173614495.USD","LU1048596156.SGD","LU0607220059.USD","IE00BZ08YS42.EUR","BK4581","TCEHY","MPNGY","LU0633140560.USD","SG9999001226.SGD","LU0823397285.USD","IE0032834883.USD","HK0000352291.HKD","LU0605514214.HKD","LU1064131003.USD","LU0106259558.USD","BK1526","LU0169518387.USD","LU0417516902.SGD","LU0823426308.USD","IE0003795394.USD","LU2039709279.SGD","LU0431992006.USD","600938","LU1267930227.SGD","LU0228367735.SGD","LU0345769128.USD","LU1770036033.HKD","SG9999014906.USD","BK4554","HK0000306685.HKD","IE0032431581.USD","LU0577902371.SGD","LU0203347892.USD","BK4526","SG9999003461.SGD","LU0117841782.USD","LU0348723411.USD","SG9999002562.SGD","BK1502","LU2362541513.USD","LU2476274720.SGD","LU0348805143.USD","LU0315179316.USD","02228","LU0516423174.USD","LU1046422090.SGD","SGXZ81163826.USD","LU0348788117.USD","LU0828237940.HKD","LU0048388663.USD","LU2265009873.SGD","LU1868837565.USD","LU1969619763.USD","LU0370786039.SGD","IE0008368304.USD","LU1152091754.HKD","LU1323998911.USD","LU0417516571.SGD","09988","BK1575","LU1956131251.USD","01810","LU1823568750.SGD","LU1993786604.SGD","LU2106854487.HKD","LU0589944569.HKD","LU0738912210.USD","LU1224444064.USD","SG9999014898.SGD","LU0608807946.USD","LU0588545490.SGD","LU1718418525.SGD","BK1161","LU0106252389.USD","LU0359201885.HKD","02269","LU2362540622.SGD","LU0873338254.USD","LU0553294199.USD","LU2476274308.USD","688331","LU1226288170.HKD","LU0210533765.USD","LU0488056044.USD","LU1235294995.USD","LU2148510915.USD","BK1205","LU0210526637.USD","IE00BQXX3F31.USD","LU0348784397.USD","LU1720051017.SGD","LU0345769631.USD","LU0197773160.USD","LU0096374516.USD","LU1439103000.SGD","LU0359201612.USD","BK4588","LU0197773673.USD","BK1193","IE00BF5LJ272.USD","LU1008478684.HKD","LU1734074674.USD","LU1003077747.HKD","LU1810669033.SGD","LU0067412154.USD","LU2097828631.EUR","LU1102505929.USD","LU0469268626.HKD","LU1201861165.SGD","LU1808992512.USD","LU0878005551.USD","LU0117844026.USD","LU1917777945.USD","BK4587","LU1303224171.USD","BK1095","LU0516422952.EUR","LU0540923850.HKD","IE00B031HY20.USD","LU0456846285.SGD","LU0456842615.SGD","SG9999018865.SGD","BK4533","LU0329678170.USD","LU2357305700.SGD","IE00BFMHRM44.USD","LU2045819591.USD","LU0107464264.USD","LU0345776255.USD","LU2097829019.USD","LU2488822045.USD","LU0455707207.USD","LU0293314216.USD","BK1558","LU0080751232.USD","LU0868486357.SGD","LU0348783233.USD","LU0588545730.USD","LU0878004406.USD","LU1688375341.USD","LU2097828557.USD","IE00BMPRXR70.SGD","BK1141","LU0949170772.SGD","LU0315178854.USD","SG9999006597.SGD","LU0823397103.USD","SG9999014914.USD","BK1233","BK1614","SGXZ51526630.SGD","LU0737861699.HKD","LU0132412106.USD","LU0214875030.USD","BK1604","LU1880383440.USD","LU0254981946.USD","LU2177674079.SGD","LU0070217475.USD","IE00B29SXG58.USD","LU2237443895.HKD","MIUmain","LU0862451837.USD","LU1481107354.HKD","LU0163747925.USD","LU0786609619.USD","LU1868838027.USD","LU2317271919.USD","IE00B8HQ1Z84.USD","LU0463099449.HKD","BK1536","LU0327786744.USD","LU2125910500.SGD","LU0054450605.USD","LU1961090484.USD","09995","LU0128525689.USD","IE00B031HW06.USD","BK4220","LU0594300179.USD","BK1249","LU0572940350.SGD","LU2097828714.EUR","LU1044874839.SGD","LU0140636845.USD","BK1584","BK1516","LU0611395673.USD","688981","BK4503","BK0214","LU0211977185.USD","LU0449515922.USD","LU0577902611.USD","LU1497733557.USD","LU2251237488.HKD","00883","IE0003851619.USD","LU1224709979.USD","HBBD.SI","80883","89988","LU0384037296.USD","LU1115378108.SGD","LU0229945570.USD","LU0188438112.USD","LU0211331839.USD"],"gpt_icon":1},{"id":"1114859504","title":"Hong Kong Stock Concept Tracking | China's NMPA Optimizes Review and Approval Process for Clinically Urgent Overseas Drugs, Sustaining High Growth Momentum in Innovative Medicines (Including Concept Stocks)","url":"https://stock-news.laohu8.com/highlight/detail?id=1114859504","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114859504?lang=en_us&edition=fundamental","pubTime":"2026-01-08 08:18","pubTimestamp":1767831512,"startTime":"0","endTime":"0","summary":"The National Medical Products Administration (NMPA) has announced further optimizations to the review and approval process for clinically urgent drugs already marketed overseas, aiming to accelerate...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"de4be8e90342c7505536e308e38cab46","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU2476274720.SGD","LU2778985437.USD","LU0348735423.USD","LU1720050803.USD","LU0348827113.USD","IE00B543WZ88.USD","LU0348784397.USD","LU0417516738.SGD","BK1588","LU2399975544.HKD","LU0348783233.USD","LU0348766576.USD","LU0417516902.SGD","LU2488822045.USD","LU0348825331.USD","159992","IE00B5MMRT66.SGD","LU0634319403.HKD","BK1574","BK1191","LU0561508036.HKD","00013","LU2476274308.USD","BK1587","LU0540923850.HKD","LU1961090484.USD","IE00BPRC5H50.USD","LU0348767384.USD","LU1794554557.SGD","09926","LU0417516571.SGD","06978"],"gpt_icon":0},{"id":"1102847137","title":"HK Stock Movement | AKESO (09926) Rises Over 6% Again as Ivonescimab Labeling Receives Major Update Including AK112-301 Study Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1102847137","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102847137?lang=en_us&edition=fundamental","pubTime":"2026-01-07 11:30","pubTimestamp":1767756622,"startTime":"0","endTime":"0","summary":"AKESO (09926) surged more than 6% again. At the time of writing, the stock was up 6.15% to HK$127.8, with a turnover of HK$789 million. On the news front, AKESO announced that the National Medical...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348767384.USD","LU0634319403.HKD","LU0348766576.USD","LU2476274308.USD","LU2476274720.SGD","LU1720050803.USD","LU1961090484.USD","LU0417516571.SGD","LU1794554557.SGD","LU0417516902.SGD","IE00BPRC5H50.USD","LU2399975544.HKD","LU0348783233.USD","LU0540923850.HKD","LU0348735423.USD","LU0561508036.HKD","BK1161","LU0417516738.SGD","IE00B5MMRT66.SGD","LU0348827113.USD","BK1574","LU2778985437.USD","LU0348825331.USD","LU0348784397.USD","IE00B543WZ88.USD","09926","LU2488822045.USD"],"gpt_icon":0},{"id":"2601431828","title":"Akeso's Ivonescimab Shows Significant Survival Benefits in HARMONi-A Phase III NSCLC Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2601431828","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601431828?lang=en_us&edition=fundamental","pubTime":"2026-01-07 10:51","pubTimestamp":1767754275,"startTime":"0","endTime":"0","summary":"Akeso Inc. has announced a significant label update for its PD-1/VEGF bispecific antibody, ivonescimab, following approval by the National Medical Products Administration in China. The updated label is based on final analysis data from the AK112-301/HARMONi-A Phase III study, which demonstrated statistically significant improvements in both progression-free survival  and overall survival  for ivonescimab in combination with chemotherapy in patients with locally advanced or metastatic non-squamous non-small cell lung cancer  that had progressed after EGFR-TKI therapy. The final OS analysis, with a median follow-up of 32.5 months, showed a 26% reduction in the risk of death  and a 54% reduction in the risk of disease progression or death  compared to chemotherapy alone. No new safety signals were identified. These results have already been presented and led to the approval and inclusion of ivonescimab in China’s National Reimbursement Drug List for both post-EGFR-TKI and first-line PD-L1","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDL459XPZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348766576.USD","LU2476274720.SGD","LU0417516738.SGD","LU2778985437.USD","IE00BPRC5H50.USD","LU0540923850.HKD","IE00B543WZ88.USD","IE00B5MMRT66.SGD","LU0561508036.HKD","LU0417516571.SGD","BK1574","LU0348783233.USD","LU0348825331.USD","LU0348767384.USD","LU0348784397.USD","LU2399975544.HKD","LU1720050803.USD","LU1794554557.SGD","LU2488822045.USD","BK1161","LU0417516902.SGD","LU1961090484.USD","LU2476274308.USD","09926","LU0348827113.USD","LU0348735423.USD","LU0634319403.HKD"],"gpt_icon":0},{"id":"1155519341","title":"HK Movers | Innovative Drug Stocks Jump With TYK Medicines up 14%","url":"https://stock-news.laohu8.com/highlight/detail?id=1155519341","media":"Tiger Newspress","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155519341?lang=en_us&edition=fundamental","pubTime":"2026-01-07 09:57","pubTimestamp":1767751062,"startTime":"0","endTime":"0","summary":"Innovative drug stocks jumped in Hong Kong. TYK Medicines rose 14%; Lepu Biopharma rose 5%; Akeso and Hengrui Pharm rose 4%; HUTCHMED rose 3%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8cf272575aa59c1c9fc76dc7d5dd9c50","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410","01276","02157","09926","00013"],"gpt_icon":0},{"id":"2600084307","title":"Asian Stocks That Could Be Trading Below Their Estimated Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2600084307","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600084307?lang=en_us&edition=fundamental","pubTime":"2026-01-01 12:07","pubTimestamp":1767240460,"startTime":"0","endTime":"0","summary":"As Asian markets continue to navigate a landscape of mixed economic indicators and moderate growth projections, investors are increasingly on the lookout for opportunities that may be undervalued amidst these conditions. Identifying stocks trading below their estimated value can offer potential advantages in such an environment, where careful analysis of fundamentals and market positioning is key to uncovering promising investments.","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6022000-choice2-main-header/1585186808155","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6022000-choice2-main-header/1585186808155"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/sg/healthcare/sgx-ulg/ultragreenai-shares/news/asian-stocks-that-could-be-trading-below-their-estimated-val","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/sg/healthcare/sgx-ulg/ultragreenai-shares/news/asian-stocks-that-could-be-trading-below-their-estimated-val","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0417516902.SGD","LU2399975544.HKD","BK1574","LU2778985437.USD","IE00BPRC5H50.USD","IE00B5MMRT66.SGD","LU1961090484.USD","LU2476274308.USD","LU1794554557.SGD","LU1720050803.USD","ULG.SI","LU0348767384.USD","LU0348827113.USD","LU0348825331.USD","LU0561508036.HKD","LU0634319403.HKD","LU0417516738.SGD","09926","LU2476274720.SGD","LU0348766576.USD","LU0348784397.USD","LU0348735423.USD","BK6103","LU0348783233.USD","LU0540923850.HKD","BK1161","LU2488822045.USD","LU0417516571.SGD","IE00B543WZ88.USD"],"gpt_icon":0},{"id":"2592731990","title":"The Bull Case For Akeso (SEHK:9926) Could Change Following FDA Clearance Of Global Gastric Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2592731990","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592731990?lang=en_us&edition=fundamental","pubTime":"2025-12-17 15:21","pubTimestamp":1765956090,"startTime":"0","endTime":"0","summary":"Akeso has recently reported a series of oncology milestones, including FDA approval to start a global Phase III trial of cadonilimab in advanced HER2‑negative gastric cancer and new Phase II/III data on ivonescimab in triple‑negative breast cancer and squamous non‑small cell lung cancer.\nTogether, these updates underscore Akeso’s push to position its bispecific antibodies as potential new standards of care across multiple solid tumors, supported by both efficacy and quality‑of‑life...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/the-bull-case-for-akeso-sehk9926-could-change-following-fda","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9926/akeso-shares/news/the-bull-case-for-akeso-sehk9926-could-change-following-fda","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1574","LU0634319403.HKD","LU1794554557.SGD","LU0348827113.USD","LU0348784397.USD","IE00B543WZ88.USD","LU0540923850.HKD","LU0348735423.USD","LU2778985437.USD","LU0348825331.USD","LU1961090484.USD","LU0417516571.SGD","LU0561508036.HKD","LU2488822045.USD","LU0348767384.USD","LU2399975544.HKD","BK1161","IE00BPRC5H50.USD","IE00B5MMRT66.SGD","09926","LU2476274720.SGD","LU0348766576.USD","LU0417516902.SGD","LU2476274308.USD","LU1720050803.USD","LU0417516738.SGD","LU0348783233.USD"],"gpt_icon":0},{"id":"1120569387","title":"FIRST SHANGHAI Initiates \"Buy\" Rating on AKESO (09926) with Target Price of HK$144.9","url":"https://stock-news.laohu8.com/highlight/detail?id=1120569387","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120569387?lang=en_us&edition=fundamental","pubTime":"2025-12-15 16:18","pubTimestamp":1765786732,"startTime":"0","endTime":"0","summary":"FIRST SHANGHAI released a research report highlighting significant progress in AKESO's (09926) core product pipeline. Cadonilimab has been approved for cervical and gastric cancer indications and...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00227","LU1794554557.SGD","BK1574","LU0348783233.USD","IE00BPRC5H50.USD","LU0417516738.SGD","LU0634319403.HKD","BK1161","LU0540923850.HKD","LU2488822045.USD","LU0348767384.USD","LU1961090484.USD","IE00B543WZ88.USD","LU2778985437.USD","IE00B5MMRT66.SGD","LU0417516902.SGD","LU0561508036.HKD","LU0348766576.USD","LU0348825331.USD","LU1720050803.USD","LU0348827113.USD","LU0417516571.SGD","LU0348784397.USD","LU2476274308.USD","LU0348735423.USD","LU2399975544.HKD","LU2476274720.SGD","09926","BK1147"],"gpt_icon":0},{"id":"1174588607","title":"Afternoon Plunge! HUABAO HANG SENG HONG KONG STOCK CONNECT INNOVATIVE DRUG SELECTION ETF (520880) Drops 2.77% to Hit New Low, Led by Heavyweights AKESO and BEIGENE","url":"https://stock-news.laohu8.com/highlight/detail?id=1174588607","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174588607?lang=en_us&edition=fundamental","pubTime":"2025-12-15 13:40","pubTimestamp":1765777238,"startTime":"0","endTime":"0","summary":"On the afternoon of December 15, the Hong Kong Stock Connect innovative drug sector accelerated its decline, with the HUABAO HANG SENG HONG KONG STOCK CONNECT INNOVATIVE DRUG SELECTION ETF (520880)...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","ONC","IE00B5MMRT66.SGD","LU0348735423.USD","LU1794554557.SGD","BK4526","LU2488822045.USD","BK4139","LU0307460666.USD","520880","LU0348825331.USD","LU1969619763.USD","LU2328871848.SGD","LU2476274308.USD","LU0348827113.USD","LU0588546209.SGD","LU0561508036.HKD","688235","LU0417516738.SGD","LU1251922891.USD","LU0417516902.SGD","LU2399975544.HKD","BK0239","LU0540923850.HKD","LU1720050803.USD","LU1719994722.HKD","LU1961090484.USD","BK1161","IE00BPRC5H50.USD","06160","LU0348784397.USD","LU0417516571.SGD","BK1583","LU0348783233.USD","BK4585","BK1500","BK1588","IE00B543WZ88.USD","LU1770034418.SGD","LU2476274720.SGD","LU2778985437.USD","LU0634319403.HKD","09926","LU0348766576.USD","LU0348767384.USD","LU1303224171.USD"],"gpt_icon":0},{"id":"1163186525","title":"AKESO Surges 6.8% After Major Announcement; Innovative Drug Leaders Rally, High-Beta HKSC Innovative Drug ETF (520880) Reverses Losses to Gain Over 1%","url":"https://stock-news.laohu8.com/highlight/detail?id=1163186525","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163186525?lang=en_us&edition=fundamental","pubTime":"2025-12-12 14:41","pubTimestamp":1765521702,"startTime":"0","endTime":"0","summary":"On the afternoon of December 12, the Hong Kong Stock Connect (HKSC) innovative drug sector rebounded, with the high-beta HKSC Innovative Drug ETF (520880) turning positive and extending gains to over...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","IE00B5MMRT66.SGD","LU0348767384.USD","IE00B543WZ88.USD","LU2399975544.HKD","LU0348783233.USD","LU1794554557.SGD","LU0417516738.SGD","IE00BPRC5H50.USD","159992","BK1574","LU2778985437.USD","09926","LU0348735423.USD","LU0348825331.USD","LU2488822045.USD","LU0417516571.SGD","LU0348784397.USD","LU0417516902.SGD","06978","LU1720050803.USD","LU2476274720.SGD","LU2476274308.USD","520880","LU0348766576.USD","LU0540923850.HKD","LU0348827113.USD","LU0561508036.HKD","LU1961090484.USD","LU0634319403.HKD"],"gpt_icon":0},{"id":"1179623757","title":"HK Stock Movement | AKESO (09926) Rises Over 3% Again as FDA Approves Global Phase III Trial for Cadonilimab in First-Line Gastric Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1179623757","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179623757?lang=en_us&edition=fundamental","pubTime":"2025-12-12 11:17","pubTimestamp":1765509473,"startTime":"0","endTime":"0","summary":"AKESO (09926) surged over 3% again, reaching HK$121.9 by the time of writing, with a trading volume of HK$271 million. The company announced via its official WeChat account that the U.S. Food and...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348825331.USD","LU1794554557.SGD","LU0348783233.USD","LU0348766576.USD","LU1961090484.USD","LU0561508036.HKD","LU2488822045.USD","LU0348735423.USD","LU0417516571.SGD","LU0417516738.SGD","LU2778985437.USD","LU0540923850.HKD","LU0348784397.USD","IE00BPRC5H50.USD","LU0348827113.USD","LU2476274308.USD","LU2476274720.SGD","BK1574","LU0348767384.USD","LU1720050803.USD","LU0417516902.SGD","BK1161","LU0634319403.HKD","IE00B543WZ88.USD","LU2399975544.HKD","09926","IE00B5MMRT66.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.akesobio.com","stockEarnings":[{"period":"1week","weight":-0.0524},{"period":"1month","weight":-0.023},{"period":"3month","weight":-0.0265},{"period":"6month","weight":-0.2937},{"period":"1year","weight":0.8143},{"period":"ytd","weight":-0.023}],"compareEarnings":[{"period":"1week","weight":0.0238},{"period":"1month","weight":0.0685},{"period":"3month","weight":0.0571},{"period":"6month","weight":0.1175},{"period":"1year","weight":0.3541},{"period":"ytd","weight":0.0685}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Akeso Inc is an investment holding company dedicated to the research, development, manufacturing and commercialization of antibody drugs that are affordable to patients worldwide. The Company’s programs covering the therapeutic areas of oncology, autoimmune and metabolic diseases. The Company's products mainly include cadonilimab (PD-1/CTLA-4), ivonescimab (PD-1/VEGF), Ligufalimab (AK117, CD47), Pulocimab (AK109, VEGFR-2), ANNIKO (penpulimab, PD-1), and tagitanlimab (PD-L1) used in oncology fields as well as ebronucimab (PCSK9), ebdarokimab (IL-12/IL-23), and Gumokimab (AK111, IL-17) used in metabolic and autoimmune therapeutic fields.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.003338},{"month":2,"riseRate":0.4,"avgChangeRate":0.029178},{"month":3,"riseRate":0.4,"avgChangeRate":-0.035342},{"month":4,"riseRate":0.8,"avgChangeRate":0.041218},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.003133},{"month":6,"riseRate":0.666667,"avgChangeRate":0.133235},{"month":7,"riseRate":0.5,"avgChangeRate":0.087867},{"month":8,"riseRate":0.5,"avgChangeRate":-0.007754},{"month":9,"riseRate":0.5,"avgChangeRate":0.036209},{"month":10,"riseRate":0.5,"avgChangeRate":0.046029},{"month":11,"riseRate":1,"avgChangeRate":0.102206},{"month":12,"riseRate":0.333333,"avgChangeRate":0.028279}],"exchange":"SEHK","name":"AKESO","nameEN":"AKESO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"AKESO(09926),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest AKESO(09926) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"AKESO,09926,AKESO股票,AKESO股票老虎,AKESO股票老虎国际,AKESO行情,AKESO股票行情,AKESO股价,AKESO股市,AKESO股票价格,AKESO股票交易,AKESO股票购买,AKESO股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"AKESO(09926),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest AKESO(09926) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}